Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomusti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Mol Sci
Hlavní autoři: Capper, David, von Deimling, Andreas, Brandes, Alba A., Carpentier, Antoine F., Kesari, Santosh, Sepulveda-Sanchez, Juan M., Wheeler, Helen R., Chinot, Olivier, Cher, Lawrence, Steinbach, Joachim P., Specenier, Pol, Rodon, Jordi, Cleverly, Ann, Smith, Claire, Gueorguieva, Ivelina, Miles, Colin, Guba, Susan C., Desaiah, Durisala, Estrem, Shawn T., Lahn, Michael M., Wick, Wolfgang
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454908/
https://ncbi.nlm.nih.gov/pubmed/28481241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18050995
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky